on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Teams Up with TriPart for Product Launch in Turkey
Viromed Medical AG, a leader in medical technology and cold plasma innovation, has announced a new distribution deal with TriPart TITAN GmbH & Co. KG. This collaboration will facilitate the introduction of Viromed's ViroCAP® and PulmoPlas® in Turkey, marking a significant step in the company's international expansion efforts. The rollout of these products is scheduled for the first quarter of 2026.
As part of the agreement, TriPart will procure an initial 5,000 units of the ViroCAP®, a mobile device designed to treat skin conditions using cold atmospheric plasma. Additionally, 750 units of the PulmoPlas®, aimed at preventing and treating ventilator-associated pneumonia, will be included. These devices are intended for use in hospitals and by general practitioners and specialists.
CEO Uwe Perbandt highlights Turkey's strategic importance due to its large population and healthcare sector's potential. Production of ViroCAP® devices will be managed by relyon plasma GmbH, ensuring supply to international markets.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news